{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:48Z","timestamp":1786207368909,"version":"build-2736575974"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1245\/s10434-026-20108-2","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T18:41:02Z","timestamp":1782585662000},"page":"7914-7915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflections: Neoadjuvant Therapy and Post-Recurrence Overall Survival in Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-1228","authenticated-orcid":false,"given":"Yawen","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"20108_CR1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-20017-4","author":"Y Dong","year":"2026","unstructured":"Dong Y, Pereyra D, Podrascanin V, et al. The effect of neoadjuvant therapy on post-recurrence overall survival after curative resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2026. https:\/\/doi.org\/10.1245\/s10434-026-20017-4.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20108_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol."},{"issue":"11","key":"20108_CR3","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1245\/s10434-020-09536-w","volume":"28","author":"MC Mason","year":"2021","unstructured":"Mason MC, Massarweh NN, Tzeng CD, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol. 2021;28(11):6725\u201335. https:\/\/doi.org\/10.1245\/s10434-020-09536-w.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"20108_CR4","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","volume":"30","author":"SK Maithel","year":"2023","unstructured":"Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30(11):6558\u201366. https:\/\/doi.org\/10.1245\/s10434-023-13809-5.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"20108_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","volume":"32","author":"TS Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab TS, Bridgewater J, Normanno N. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Ann Oncol. 2021;32(9):1111\u201326. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.012.","journal-title":"Ann Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20108-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:49:24Z","timestamp":1786204164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20108-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["20108"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20108-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yawen Dong and Patrick Starlinger have no conflict of interest to disclose.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}